eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.my news
.
.
.
.
advertisement
.treatment delays are also causing needless anxiety and distress to patients as well as putting lives at serious risk (file pic)
.